While deal volumes have slowed in recent years, in line with overall M&A activity, deals in the life sciences sector appeared to be picking up slightly at the end of 2023. In 2024, lower valuations are expected to provide pharmaceutical companies with additional transaction and acquisition opportunities at a later stage to strengthen portfolios in the face of impending patent expiry, and at an earlier stage as part of a highly selective strategy.
Panellists will look into this seeming resurgence of M&A and its implications for early-stage deals, discussing funding availability, business development prospects and deal pattern observations.
What trends are observed in recent M&A deals? What is the reality of M&As and which diversity of patterns can we observe in terms of deals? What is nature of deals for mid-size companies? What are BD heads observing and how are they responding? What is the impact of IRA on R&D and M&As strategies? What is the balance between acquisitions and partnerships in global strategies? Is the resurgence of M&A activity creating more opportunities or challenges for early-stage dealmaking? What are the therapeutic areas of value for M&As? What are the consequences for biotechs in a pre-deal environment? Are investors more likely to take risks earlier on as a result? What will large pharmas and investors be looking for in 2025?
